CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 99 enrolled
Drug / intervention
Etanercept +1 moredrug
Likely dose
Etanercept 50 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00640393
NCT00640393Phase 4Completed
CompareCT.gov

A Randomized Study Combining Etanercept and Short Courses of Narrow-Band UVB in Patients With Psoriasis Vulgaris

Innovaderm Research Inc.·interventional·Posted Mar 21, 2008·Updated Sep 9, 2011

In Brief

A Phase 4 clinical trial evaluating Etanercept and nbUVB for Psoriasis Vulgaris. Completed, enrolled 99 participants across 10 sites.

Detailed Summary

This study will provide data on the addition of narrow band ultra violet B (nbUVB) phototherapy to participants who have not shown an excellent response to three months of etanercept.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriasis Vulgaris
CountriesCanada
CollaboratorsAmgen

Timeline

Phase 4CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMar 21, 2008
Enrollment StartApr 1, 2008
Primary CompletionFeb 1, 2010
Study CompletionMar 1, 2010
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 18.3 years ago

Interventions

Etanerceptdrug

Etanercept 50 mg, subcutaneous (SC) injection.

nbUVBdevice